REPORTS

Let’s Pullulate and Expand Your Business

AT1 Receptor Antagonists Market - Global Professional Analysis and Forecast to 2026

Feb 22, 2020  |  207 PAGES  |  REPORT CODE: CMM268106
  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • INDUSTRY COVERAGE

The worldwide AT1 Receptor Antagonists market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 4.9% during the forecast period.

This report presents the market size and development trends by detailing the AT1 Receptor Antagonists market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the AT1 Receptor Antagonists market will be shown in this report. In short, this report will comprehensively reveal the characteristics of AT1 Receptor Antagonists industry and will help you to build a panoramic view of the industrial development.

AT1 Receptor Antagonists Market, By Type:

  • Valsartan

  • Telmisartan

  • Losartan

  • Irbesartan

  • Azilsartan

  • Olmesartan

AT1 Receptor Antagonists Market, By Application:

  • Hypertension

  • Cardiovascular Diseases

  • Kidney Diseases

  • Other

Some of the leading players are as follows:

  • Teva Pharmaceutical

  • Bayer

  • Astra Zeneca

  • Novartis

  • Bristol-Myers Squibb

  • Sanofi SA

  • Jhonson and Johnson

  • Merck

  • GSK

  • Eli Lilly and Company

  • Pfizer

Geographically, Major regions are analyzed in details are as follows:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Table of Contents

1 Methodology and Scope

  • 1.1 Market Segmentation & Scope

    • 1.1.1 Technology Type

    • 1.1.2 Product

    • 1.1.3 Application

    • 1.1.4 Regional scope

    • 1.1.5 Estimates and forecast timeline

  • 1.2 Research Methodology

  • 1.3 Information Procurement

    • 1.3.1 Purchased database

    • 1.3.2 Internal database

    • 1.3.3 Secondary sources

    • 1.3.4 Primary research

    • 1.3.5 Details of primary research

  • 1.4 Information or Data Analysis

    • 1.4.1 Data analysis models

  • 1.5 Market Formulation & Validation

  • 1.6 Model Details

    • 1.6.1 Commodity flow analysis

    • 1.6.2 Volume price analysis

  • 1.7 List of Secondary Sources

  • 1.8 List of Abbreviations

2 Executive Summary

  • 2.1 Market Outlook

  • 2.2 Segment Outlook

3 Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook

  • 3.1.1 Parent market outlook

    • 3.1.2 Ancillary market outlook

  • 3.2 Market Segmentation

    • 3.2.1 Analysis

  • 3.3 Market Dynamics

    • 3.3.1 Market driver analysis

    • 3.3.2 Market restraint analysis

    • 3.3.3 Industry opportunities

  • 3.4 Penetration & Growth Prospect Mapping

    • 3.4.1 Penetration & growth prospect mapping analysis

  • 3.5 Business Environment Analysis Tools

    • 3.5.1 Porter's five forces analysis

    • 3.5.2 PESTLE analysis

    • 3.5.3 Major deals & strategic alliances analysis

4 AT1 Receptor Antagonists Market: Technology Type Analysis

  • 4.1 AT1 Receptor Antagonists Technology Type Market Share Analysis, 2018 & 2026

  • 4.2 AT1 Receptor Antagonists Technology Type Market: Segment Dashboard

  • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

    • 4.3.1 Valsartan

    • 4.3.2 Telmisartan

    • 4.3.3 Losartan

    • 4.3.4 Irbesartan

    • 4.3.5 Azilsartan

    • 4.3.6 Olmesartan

5 AT1 Receptor Antagonists Market: Product Analysis

  • 5.1 AT1 Receptor Antagonists Product Market Share Analysis, 2018 & 2026

  • 5.2 AT1 Receptor Antagonists Product Market: Segment Dashboard

  • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

6 AT1 Receptor Antagonists Market: Application Analysis

  • 6.1 AT1 Receptor Antagonists Application Market Share Analysis, 2018 & 2026

  • 6.2 AT1 Receptor Antagonists Application Market: Segment Dashboard

  • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

    • 6.3.1 Hypertension

    • 6.3.2 Cardiovascular Diseases

    • 6.3.3 Kidney Diseases

    • 6.3.4 Other

7 AT1 Receptor Antagonists Market: Regional Analysis

  • 7.1 AT1 Receptor Antagonists Regional Market Share Analysis, 2018 & 2026

  • 7.2 AT1 Receptor Antagonists Regional Market: Segment Dashboard

  • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

  • 7.4 List of Players at Regional Level

    • 7.4.1 North America

    • 7.4.2 Europe

    • 7.4.3 Asia Pacific

  • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

    • 7.5.1 North America

    • 7.5.2 Europe

    • 7.5.3 Asia Pacific

    • 7.5.4 Latin America

    • 7.5.5 MEA

  • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

    • 7.6.1 North America

    • 7.6.2 Europe

    • 7.6.3 Asia Pacific

    • 7.6.4 Latin America

    • 7.6.5 Middle East & Africa

8 Competitive Analysis

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

  • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

  • 8.3 Vendor Landscape

    • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

9 Company Profiles

  • 9.1 Teva Pharmaceutical

    • 9.1.1 Teva Pharmaceutical Company overview

    • 9.1.2 Financial performance

    • 9.1.3 Product benchmarking

    • 9.1.4 Strategic initiatives

    • 9.1.5 SWOT analysis

  • 9.2 Bayer

    • 9.2.1 Bayer Company overview

    • 9.2.2 Financial performance

    • 9.2.3 Product benchmarking

    • 9.2.4 Strategic initiatives

    • 9.2.5 SWOT analysis

  • 9.3 Astra Zeneca

    • 9.3.1 Astra Zeneca Company overview

    • 9.3.2 Financial performance

    • 9.3.3 Product benchmarking

    • 9.3.4 Strategic initiatives

    • 9.3.5 SWOT analysis

  • 9.4 Novartis

    • 9.4.1 Novartis Company overview

    • 9.4.2 Financial performance

    • 9.4.3 Product benchmarking

    • 9.4.4 Strategic initiatives

    • 9.4.5 SWOT analysis

  • 9.5 Bristol-Myers Squibb

    • 9.5.1 Bristol-Myers Squibb Company overview

    • 9.5.2 Financial performance

    • 9.5.3 Product benchmarking

    • 9.5.4 Strategic initiatives

    • 9.5.5 SWOT analysis

  • 9.6 Sanofi SA

    • 9.6.1 Sanofi SA Company overview

    • 9.6.2 Financial performance

    • 9.6.3 Product benchmarking

    • 9.6.4 Strategic initiatives

    • 9.6.5 SWOT analysis

  • 9.7 Jhonson and Johnson

    • 9.7.1 Jhonson and Johnson Company overview

    • 9.7.2 Financial performance

    • 9.7.3 Product benchmarking

    • 9.7.4 Strategic initiatives

    • 9.7.5 SWOT analysis

  • 9.8 Merck

    • 9.8.1 Merck Company overview

    • 9.8.2 Financial performance

    • 9.8.3 Product benchmarking

    • 9.8.4 Strategic initiatives

    • 9.8.5 SWOT analysis

  • 9.9 GSK

    • 9.9.1 GSK Company overview

    • 9.9.2 Financial performance

    • 9.9.3 Product benchmarking

    • 9.9.4 Strategic initiatives

    • 9.9.5 SWOT analysis

  • 9.10 Eli Lilly and Company

    • 9.10.1 Eli Lilly and Company Company overview

    • 9.10.2 Financial performance

    • 9.10.3 Product benchmarking

    • 9.10.4 Strategic initiatives

    • 9.10.5 SWOT analysis

  • 9.11 Pfizer

    • 9.11.1 Pfizer Company overview

    • 9.11.2 Financial performance

    • 9.11.3 Product benchmarking

    • 9.11.4 Strategic initiatives

    • 9.11.5 SWOT analysis

 

The List of Tables and Figures (Totals 92 Figures and 144 Tables)

  • Figure Valsartan AT1 Receptor Antagonists market, 2015 - 2026 (USD Million)

  • Figure Telmisartan AT1 Receptor Antagonists market, 2015 - 2026 (USD Million)

  • Figure Losartan AT1 Receptor Antagonists market, 2015 - 2026 (USD Million)

  • Figure Irbesartan AT1 Receptor Antagonists market, 2015 - 2026 (USD Million)

  • Figure Azilsartan AT1 Receptor Antagonists market, 2015 - 2026 (USD Million)

  • Figure Olmesartan AT1 Receptor Antagonists market, 2015 - 2026 (USD Million)

  • Figure Hypertension market, 2015 - 2026 (USD Million)

  • Figure Cardiovascular Diseases market, 2015 - 2026 (USD Million)

  • Figure Kidney Diseases market, 2015 - 2026 (USD Million)

  • Figure Other market, 2015 - 2026 (USD Million)

  • Table List of players in North America

  • Table List of players in Europe

  • Table List of players in Asia Pacific

  • Table SWOT analysis

  • Table North America AT1 Receptor Antagonists market, by country, 2015 - 2026 (USD Million)

  • Table North America AT1 Receptor Antagonists market, by type, 2015 - 2026 (USD Million)

  • Table North America AT1 Receptor Antagonists market, by product, 2015 - 2026 (USD Million)

  • Table North America AT1 Receptor Antagonists market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.S. AT1 Receptor Antagonists market, by type, 2015 - 2026 (USD Million)

  • Table U.S. AT1 Receptor Antagonists market, by product, 2015 - 2026 (USD Million)

  • Table U.S. AT1 Receptor Antagonists market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Canada AT1 Receptor Antagonists market, by type, 2015 - 2026 (USD Million)

  • Table Canada AT1 Receptor Antagonists market, by product, 2015 - 2026 (USD Million)

  • Table Canada AT1 Receptor Antagonists market, by application, 2015 - 2026 (USD Million)

  • Table Europe AT1 Receptor Antagonists market, by country, 2015 - 2026 (USD Million)

  • Table Europe AT1 Receptor Antagonists market, by type, 2015 - 2026 (USD Million)

  • Table Europe AT1 Receptor Antagonists market, by product, 2015 - 2026 (USD Million)

  • Table Europe AT1 Receptor Antagonists market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.K. AT1 Receptor Antagonists market, by type, 2015 - 2026 (USD Million)

  • Table U.K. AT1 Receptor Antagonists market, by product, 2015 - 2026 (USD Million)

  • Table U.K. AT1 Receptor Antagonists market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Germany AT1 Receptor Antagonists market, by type, 2015 - 2026 (USD Million)

  • Table Germany AT1 Receptor Antagonists market, by product, 2015 - 2026 (USD Million)

  • Table Germany AT1 Receptor Antagonists market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table France AT1 Receptor Antagonists market, by type, 2015 - 2026 (USD Million)

  • Table France AT1 Receptor Antagonists market, by product, 2015 - 2026 (USD Million)

  • Table France AT1 Receptor Antagonists market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Italy AT1 Receptor Antagonists market, by type, 2015 - 2026 (USD Million)

  • Table Italy AT1 Receptor Antagonists market, by product, 2015 - 2026 (USD Million)

  • Table Italy AT1 Receptor Antagonists market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Spain AT1 Receptor Antagonists market, by type, 2015 - 2026 (USD Million)

  • Table Spain AT1 Receptor Antagonists market, by product, 2015 - 2026 (USD Million)

  • Table Spain AT1 Receptor Antagonists market, by application, 2015 - 2026 (USD Million)

  • Table Asia Pacific AT1 Receptor Antagonists market, by country, 2015 - 2026 (USD Million)

  • Table Asia Pacific AT1 Receptor Antagonists market, by type, 2015 - 2026 (USD Million)

  • Table Asia Pacific AT1 Receptor Antagonists market, by product, 2015 - 2026 (USD Million)

  • Table Asia Pacific AT1 Receptor Antagonists market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table China AT1 Receptor Antagonists market, by type, 2015 - 2026 (USD Million)

  • Table China AT1 Receptor Antagonists market, by product, 2015 - 2026 (USD Million)

  • Table China AT1 Receptor Antagonists market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Japan AT1 Receptor Antagonists market, by type, 2015 - 2026 (USD Million)

  • Table Japan AT1 Receptor Antagonists market, by product, 2015 - 2026 (USD Million)

  • Table Japan AT1 Receptor Antagonists market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table India AT1 Receptor Antagonists market, by type, 2015 - 2026 (USD Million)

  • Table India AT1 Receptor Antagonists market, by product, 2015 - 2026 (USD Million)

  • Table India AT1 Receptor Antagonists market, by application, 2015 - 2026 (USD Million)

  • Table Latin America AT1 Receptor Antagonists market, by country, 2015 - 2026 (USD Million)

  • Table Latin America AT1 Receptor Antagonists market, by type, 2015 - 2026 (USD Million)

  • Table Latin America AT1 Receptor Antagonists market, by product, 2015 - 2026 (USD Million)

  • Table Latin America AT1 Receptor Antagonists market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Brazil AT1 Receptor Antagonists market, by type, 2015 - 2026 (USD Million)

  • Table Brazil AT1 Receptor Antagonists market, by product, 2015 - 2026 (USD Million)

  • Table Brazil AT1 Receptor Antagonists market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Mexico AT1 Receptor Antagonists market, by type, 2015 - 2026 (USD Million)

  • Table Mexico AT1 Receptor Antagonists market, by product, 2015 - 2026 (USD Million)

  • Table Mexico AT1 Receptor Antagonists market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Argentina AT1 Receptor Antagonists market, by type, 2015 - 2026 (USD Million)

  • Table Argentina AT1 Receptor Antagonists market, by product, 2015 - 2026 (USD Million)

  • Table Argentina AT1 Receptor Antagonists market, by application, 2015 - 2026 (USD Million)

  • Table MEA AT1 Receptor Antagonists market, by country, 2015 - 2026 (USD Million)

  • Table MEA AT1 Receptor Antagonists market, by type, 2015 - 2026 (USD Million)

  • Table MEA AT1 Receptor Antagonists market, by product, 2015 - 2026 (USD Million)

  • Table MEA AT1 Receptor Antagonists market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table South Africa AT1 Receptor Antagonists market, by type, 2015 - 2026 (USD Million)

  • Table South Africa AT1 Receptor Antagonists market, by product, 2015 - 2026 (USD Million)

  • Table South Africa AT1 Receptor Antagonists market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Nigeria AT1 Receptor Antagonists market, by type, 2015 - 2026 (USD Million)

  • Table Nigeria AT1 Receptor Antagonists market, by product, 2015 - 2026 (USD Million)

  • Table Nigeria AT1 Receptor Antagonists market, by application, 2015 - 2026 (USD Million)

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Company market position analysis

  • Table Company Profiles

  • Table Teva Pharmaceutical Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Bayer Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Astra Zeneca Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Novartis Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Bristol-Myers Squibb Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Sanofi SA Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Jhonson and Johnson Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Merck Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table GSK Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Eli Lilly and Company Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Pfizer Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

Report Purchase

reports
$3850
$7700
BUY NOWClick MeBUY NOW
top